Steve Miller - 18 Aug 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Operating Officer
Signature
/s/ Steve Miller
Issuer symbol
CPRX
Transactions as of
18 Aug 2022
Net transactions value
-$1,650,422
Form type
4
Filing time
19 Aug 2022, 17:03:19 UTC
Previous filing
16 Feb 2022
Next filing
15 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $299,995 +118,575 +16% $2.53* 880,299 18 Aug 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $1,607,758 -118,575 -13% $13.56 761,724 18 Aug 2022 Direct F1, F3
transaction CPRX Common stock, par value $0.001 per share Options Exercise $79,505 +31,425 +4.1% $2.53* 793,149 18 Aug 2022 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale $422,163 -31,425 -4% $13.43 761,724 18 Aug 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Award $0 -118,575 -7.4% $0.000000 1,492,425 18 Aug 2022 Common Stock 118,575 $2.53 Direct F4
transaction CPRX Options to purchase common stock Award $0 -31,425 -2.1% $0.000000 1,461,000 18 Aug 2022 Common Stock 31,425 $2.53 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold in various lots from $13.37 to $13.66 per share. The listed sales price represents a weighted average price for the shares sold.
F2 Shares were sold in various lots from $13.30 to $13.54 per share. The listed sales price represents a weighted average price for the shares sold.
F3 Shares were sold to cover exercise price of options, tax withholding requirements (if applicable) and for personal reasons. Shares were not sold as a result of any disagreement with the Company and Dr. Miller remains an officer of the Company.
F4 Options vested in three annual tranches beginning on December 30, 2016.